Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2739 - Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer


Jakob Schou


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


J.V. Schou1, B.S. Sørensen2, F.O. Larsen3, R. Abrantes2, A. Boysen4, J.S. Johansen3, B. Vittrup Jensen3, D. Nielsen3, K. Spindler4

Author affiliations

  • 1 Department Of Oncology, Herlev Hospital, D2730 - Herlev/DK
  • 2 Department Of Experimental Clinical Oncology, Århus University Hospital, 8000 - Århus/DK
  • 3 Department Of Oncology, Herlev Hospital, 2730 - Herlev/DK
  • 4 Department Of Oncology, Århus University Hospital, 8000 - Århus/DK


Abstract 2739


Treatment of patients with locally advanced rectal cancer (LARC) is based on a combination of chemo-radiotherapy (CRT) and surgery. The rate of distant recurrences remains over 25% and biomarkers to detect treatment failure are urgently needed. Circulating cell-free DNA (cfDNA) in plasma is a mixture of normal and cancer specific DNA segments, and a promising biomarker in patients with colorectal cancer. Only few studies have examined the potential utility of cfDNA in LARC but suggest a correlation between cfDNA and the response to neoadjuvant CRT. The aim of our study was to investigate plasma cfDNA in patients with LARC treated with induction chemotherapy (ICT), CRT and surgery.


A total of 124 patients with LARC were prospectivily included at Herlev Hospital, Denmark, from 2010-14. Patients were treated with neoadjuvant CRT and 52 also received 1-3 cycles of ICT with CAPEOX. Total cfDNA levels were measured by direct fluorescent assay in plasma samples obtained at baseline, after ICT and after CRT. Mann-Whitney test, Kaplan-Meier plots and Cox regression analysis were used for statistical analyses. Disease free survival (DFS) was measured from start until distant recurrence or death from any cause.


Median baseline level of cfDNA was 0.96 ng/µL (range 0.46-2.28). Baseline cfDNA did not differ between stage II & III disease (p = 0.15). Median follow-up was 54 months and 27.4% of the patients had distant recurrence during follow-up. When dividing patients in groups of cfDNA quartiles, increasing cfDNA levels were associated with impaired outcome. Patients with baseline cfDNA levels above the 75th quartile, had a higher risk of distant recurrence and shorter median RFS compared to those below, (HR 2.63; CI95%: 1.34-5.15; p = 0.008). The same applied to DFS (HR 1.97, CI95%: 1.09-1.97, p = 0.003). High cfDNA level after CRT was associated with an increased risk of distant recurrence (p = 0.052).


Our results demonstrate a strong correlation between high baseline level of cfDNA and increased risk of distant recurrence in patients with LARC treated with neo-adjuvant CRT. Consequently, cfDNA could hold potential for better pre-treatment risk assessment and as tool for individualized therapy in this setting.

Clinical trial identification

Legal entity responsible for the study

Jakob Vasehus Schou




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.